News | June 07, 2022
MEI Pharma and Kyowa Kirin report new clinical data on Zandelisib
he Phase 2 TIDAL data generated to date continue to highlight zandelisib's therapeutic profile and the potential to benefit patients
he Phase 2 TIDAL data generated to date continue to highlight zandelisib's therapeutic profile and the potential to benefit patients
The DMF#36513 demonstrates ANP’s success in the development of its “Plug and Play” drug delivery platform.
The companies will jointly identify and develop molecular glue degraders up to a clinical candidate stage.
Immune-mediated events and infusion reactions were higher with KEYTRUDA (38% vs 9%, respectively).
Susanne Kaestner joins the company as Senior Vice President, Quality and member of the Executive Team, and Dr. Thea Boehm as Vice President, Business Development.
A research group led by Ben-Gurion University of the Negev managed to produce an innovative microchip for creating sperm in a culture by using a microfluidic system.
PharmaLytica Expo to aid in chalking out pharma industry’s $130 Billion growth story by 2030
Innate to receive $5M milestone payment from AstraZeneca
GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones
Follows Zealand Pharma’s appointment of Adam Steensberg as CEO and decision to refocus strategy
Subscribe To Our Newsletter & Stay Updated
